GlassScriptPhysician profile
Edward K Stevenson
NPI 1780948893
$3,406.59
in general payments reported to CMS, 2019-2025
31 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Uveitis and Ocular Inflammatory Disease provider received nationally (typical 2025 total: $471).
See the full distribution for Uveitis and Ocular Inflammatory Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $169 · 2021: $280 · 2022: $503 · 2023: $797 · 2024: $609 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.39 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.66 | 2022-2025 | Ozurdex, Vuity |
| Genentech USA, INC. | $381.80 | 2019-2025 | Vabysmo |
| Allergan, INC. | $290.62 | 2019-2022 | |
| Astellas Pharma US INC | $285.66 | 2023-2025 | Izervay |
| Eyepoint US, INC. | $266.47 | 2020-2022 | |
| Alcon Vision LLC | $212.73 | 2021-2025 | Simbrinza, Rocklatan, Eysuvis |
| Sun Pharmaceutical Industries INC. | $163.85 | 2022-2025 | Cequa |
| Biogen, INC. | $145.99 | 2023-2024 | Byooviz |
| Amgen INC. | $130.82 | 2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $123.82 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $114.19 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $112.65 | 2023 | Xipere, Stellaris |
| Alimera Sciences, INC. | $102.22 | 2022-2024 | Iluvien, Yutiq |
| Sight Sciences, INC. | $64.48 | 2022-2025 | Sion Surgical Instrument, Omni Surgical System |
| Ani Pharmaceuticals, INC. | $64.36 | 2022-2025 | Yutiq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $63.92 | 2022-2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $61.72 | 2021-2022 | |
| Astellas Pharma Global Development | $59.00 | 2025 | Izervay |
| Rxsight INC | $37.88 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $27.50 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $27.05 | 2023 | Veritas Vision System |
| Coherus Oncology, INC. | $26.41 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.76 | 2020 | |
| Rayner Intraocular Lenses Limited | $23.14 | 2023 | Rayone Spheric, Omidria, Rayone Emv |
| Abb Con-Cise Optical Group LLC | $18.16 | 2019 | |
| Harrow Eye, LLC | $17.78 | 2025 | Iheezo |
| Dompe US, INC. | $17.31 | 2023 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $16.86 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $15.26 | 2022 | |
| Iridex Corporation | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Stevenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.